Skip to main content
Premium Trial:

Request an Annual Quote

Evident Technologies Forms Quantum Dot Collaboration with NIST

NEW YORK, Aug. 24 (GenomeWeb News) - Evident Technologies said today that it has entered into a cooperative research and development agreement with the National Institute of Standards and Technology to investigate the use of quantum dot composite fluorescent standards for biotech instrumentation.

 

"A fluorescence standard is necessary, especially for clinical applications, where quantification is required," Clint Ballinger, CEO, of Evident, said in a statement. "It is nearly impossible to quantify the fluorescence from an assay today, but our collaboration with NIST should greatly advance the state of the art."

 

Under the CRADA, Evident will provide quantum dot composites to NIST for characterization.

 

Additional terms were not disclosed.

 

The Scan

Long COVID-19 Susceptibility Clues Contained in Blood Plasma Proteome

A longitudinal study in eBioMedicine found weeks-long blood plasma proteome shifts after SARS-CoV-2 infection, along with proteomic signatures that appeared to coincide with long Covid risk.

Tibetan Study Finds Adaptive Variant Influencing Skin Pigmentation

With a combination of phenotyping and genetic data, researchers document at PNAS a Tibetan-enriched enhancer variant influencing melanin synthesis and ultraviolet light response.

Domestication Linked to Nervous System Genes in Inbred Mouse Strains

Researchers highlighted more than 300 positively selected genes in domesticated mice, including genes linked to nervous system function or behavior in Genome Biology.

ALS Genetic Testing May Be Informative Across Age Ranges, Study Finds

Researchers in the journal Brain identified clinically actionable variants in a significant subset of older ALS patients, prompting them to point to the potential benefits of broader test use.